UCB U.S. News

18 Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Nov

19 Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Oct

22 UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21.

Categories

Archives

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Oct

22

UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Choose a Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact